Pages that link to "Q35859879"

The following pages link to Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults (Q35859879):

Displaying 11 items.

• Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients (Q37612990) (← links)
• Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells. (Q38708710) (← links)
• The Cell Biology of Cytomegalovirus: Implications for Transplantation (Q38779938) (← links)
• A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers (Q40180049) (← links)
• Pharmacokinetics and exposure-response analysis of RG7667, a combination of two anti-cytomegalovirus monoclonal antibodies, in a Phase 2a randomized trial to prevent cytomegalovirus infection in high-risk kidney transplant recipients. (Q45967035) (← links)
• Antibody therapies for the prevention and treatment of viral infections. (Q47143843) (← links)
• Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient. (Q47577035) (← links)
• Large-Scale Screening of HCMV-Seropositive Blood Donors Indicates that HCMV Effectively Escapes from Antibodies by Cell-Associated Spread (Q58738833) (← links)
• The N Terminus of Human Cytomegalovirus Glycoprotein O Is Important for Binding to the Cellular Receptor PDGFRα (Q92511027) (← links)
• Pharmacology-guided rule-based adaptive dose escalation in first-in-human studies (Q101327552) (← links)
• Modeling Human Cytomegalovirus-Induced Microcephaly in Human iPSC-Derived Brain Organoids (Q102144604) (← links)